Results 71 to 80 of about 1,710 (123)

Respiratory Oscillometry and Multimodal Lung Function Assessment of Elexacaftor/Tezacaftor/Ivacaftor Response in Children and Young Adults With Cystic Fibrosis. [PDF]

Pediatr Pulmonol
Kogias C, Sopiadou A, Fouzas S, Vantsi P, Chrysochoou EA, Desli E, Galogavrou M, Gasparis N, Hatziagorou E.   +8 more
europepmc   +1 more source

Obstetric and Neonatal Outcomes in Pregnancies From a Dedicated Cystic Fibrosis-Maternal Health Service: A Retrospective Study. [PDF]

BJOG
Scott R, Downes A, Weitnauer L, Dobra R, Singh N, Robinson R, Diable E, Collins S, Bowman E, Tobin T, Jones A, Simmonds N, Felton I.   +12 more
europepmc   +1 more source

Inhibitory Effect of <i>Curcuma xanthorrhiza</i> Extract Against SARS-CoV-2 D614G Virus-Like Particle (VLP): Implications for COVID-19 Therapy Development. [PDF]

ScientificWorldJournal
Mushlih M, Bemova M, Marzouk HA, Kusuma KH, Rohmah IN, Fitriana N, Prima A, Christina YI, Dwijayanti DR, Mustikaningtyas D, Widodo N, Djati MS, Widyarti S, Rifa'i M.   +13 more
europepmc   +1 more source

Expanding the Impact of New Cystic Fibrosis Therapies in Low- and Middle-Income Countries. [PDF]

Pediatr Pulmonol
Kerem E.
europepmc   +1 more source

The validated French CFAbd-Score reveals a lower burden of gastrointestinal symptoms in patients on Elexacaftor/Tezacaftor/Ivacaftor. [PDF]

J Pediatr Gastroenterol Nutr
Sermet-Gaudelus I, Sadrieh P, Bonnel AS, Enaud R, Wizla N, Languepin J, Nangui A, Deelawon A, Rave J, Dabelow S, Barucha A, Zagoya C, Duckstein F, Mainz JG.   +13 more
europepmc   +1 more source

Comparison of Stool Microbiome in Children with Cystic Fibrosis Treated with and Without Elexacaftor-Tezacaftor-Ivacaftor-A Pilot Study. [PDF]

Int J Mol Sci
Sankararaman S, Liu R, Sun X, Retuerto M, Schindler T, Roesch E, Sferra TJ, Drumm M, Ghannoum M, Zhang L.   +9 more
europepmc   +1 more source

Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis. [PDF]

Pediatr Pulmonol
Trost SU, Harindhanavudhi T, Wang Q, Ankireddypalli A, Simrah A, Avula S, Moheet A.   +6 more
europepmc   +1 more source

Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis. [PDF]

Respir Res
Gramegna A, Cimino G, Cipolli M, Gandini G, Calderazzo MA, Profiti A, Piedepalumbo F, Blasi F.   +7 more
europepmc   +1 more source

Elexacaftor/Tezacaftor/Ivacaftor Supports Treatment for CF with ΔI1023-V1024-CFTR. [PDF]

Int J Mol Sci
Huang Y, Gonzales Cordova JM, Penrod S, Bendy LL, Cheng PC, Sanders DB, Davis MD, Gaston B, Chmiel JF.   +8 more
europepmc   +1 more source

Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. [PDF]

Ann Am Thorac Soc
Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, Morgan SJ, Singh PK, Nichols DP, Kelly A, Solomon GM, PROMISE Study Group .   +15 more
europepmc   +1 more source